RT Journal Article
SR Electronic
T1 Antibody profiling of COVID-19 patients in an urban low-incidence region in Northern Germany
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.30.20111393
DO 10.1101/2020.05.30.20111393
A1 Werner Solbach
A1 Julia Schiffner
A1 Insa Backhaus
A1 David Burger
A1 Ralf Staiger
A1 Bettina Tiemer
A1 Andreas Bobrowski
A1 Timothy Hutchings
A1 Alexander Mischnik
YR 2020
UL http://medrxiv.org/content/early/2020/06/02/2020.05.30.20111393.abstract
AB This explorative monocentric study shows IgA and IgG antibody profiles from 110 patients with self-reported mild to moderate, or no COVID-19 related symptoms after laboratory-confirmed infection with SARS-CoV-2. The study region is in an urban and well-defined environment in a low-incidence region in Northern Germany. We found that approx. 70 % of the patients developed sustainable antibodies 3 weeks or later after the infection. In about 30 % of the patients with mild to moderate symptoms, no significant antibodies could be detected in two consecutive analyses. Conversely, out of ten patients without symptoms, four were repeatedly positive. Expectedly, six had no specific antibodies. The data indicate that antibody-positivity is a useful indicator of a previous SARS-CoV-2 infection. Negative antibodies do not rule out SARS-CoV-2 infection. Future studies need to determine the functionality of the antibodies in terms of personal protection and ability to transmit the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was carried out in accordance with the Declaration of Helsinki and the guidelines of the International Conference for Harmonization for Good Clinical Practice. The study was approved by the local Ethics Committee at the University of Luebeck.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data for submission and further analysis are available.COVID-19coronavirus disease 19ELISAenzyme-linked immunosorbent assayIgG/Aimmunoglobulin G/ArtPCRreal-time polymerase chain reactionSARS-CoV-2Severe acute respiratory syndrome coronavirus 2